ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Antibiotice S.A. Develops and manufactures generic medicines and APIs, specializing in anti-infectives.	Romania	ATB
Apellis Pharmaceuticals, Inc. Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.	United States of America	APLS
Apimeds Pharmaceuticals US, Inc. Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.	United States of America	APUS
Apogee Therapeutics, Inc. Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.	United States of America	APGE
Apollomics Inc. A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.	United States of America	APLM
Apontis Pharma AG German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.	Germany	APPH
APPLIED DNA SCIENCES INC Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.	United States of America	APDN
Applied Therapeutics, Inc. Develops treatments for rare metabolic and central nervous system (CNS) disorders.	United States of America	APLT
Aprea Therapeutics, Inc. Developing precision cancer therapies targeting DNA Damage Response for solid tumors.	United States of America	APRE
AprilBio Co.,Ltd. Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.	South Korea	397030